ProCE Banner Activity

My Thoughts on the Use of PARP Inhibitor Plus AR-Signaling Inhibitor Combinations for Our Patients With mCRPC

Clinical Thought

In this expert commentary, Rana R. McKay, MD, offers her perspective on how the latest approvals of combination therapy with a PARP inhibitor and an AR-signaling inhibitor will affect treatment choices for patients with mCRPC.

Released: September 27, 2023

Share

Faculty

Rana R. McKay

Rana R. McKay, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
University of California, San Diego
Genitourinary Oncology Team Lead
Moores Cancer Center
La Jolla, California

Provided by

Provided by Clinical Care Options, LLC., in partnership with ZERO Prostate Cancer

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC, Lilly, Merck Sharp & Dohme Corp., and Novartis.

AstraZeneca

Bayer HealthCare Pharmaceuticals Inc.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Lilly

Novartis

Partners

ZERO Prostate Cancer

ProCE Banner

Disclosure

Primary Author

Rana R. McKay, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
University of California, San Diego
Genitourinary Oncology Team Lead
Moores Cancer Center
La Jolla, California

Rana R. McKay, MD: consultant/advisor/speaker: AstraZeneca, Aveo, Bristol-Myers Squibb, Bayer, Calithera, Caris, Dendreon, Eisaix, Exelixis, Johnson & Johnson, Lilly, Myovant, Merck, Novartis, Pfizer, Sanofi, Seagen, Sorrento, Telix, Tempus; research funding (paid to institution): Artera, Bayer, BMS, Exelixis, AstraZeneca, Oncternal, Tempus.